MQS Management LLC Has $313,000 Holdings in The Cooper Companies, Inc. (NASDAQ:COO)

MQS Management LLC decreased its holdings in The Cooper Companies, Inc. (NASDAQ:COO) by 41.5% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,584 shares of the medical device company’s stock after selling 2,538 shares during the period. MQS Management LLC’s holdings in Cooper Companies were worth $313,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Benjamin F. Edwards & Company Inc. increased its position in Cooper Companies by 248.6% in the 1st quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after purchasing an additional 174 shares during the last quarter. Brown Brothers Harriman & Co. raised its position in Cooper Companies by 412.2% during the fourth quarter. Brown Brothers Harriman & Co. now owns 251 shares of the medical device company’s stock valued at $95,000 after acquiring an additional 202 shares in the last quarter. Covestor Ltd lifted its stake in Cooper Companies by 305.9% in the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock valued at $28,000 after acquiring an additional 208 shares during the last quarter. Innealta Capital LLC bought a new stake in Cooper Companies in the second quarter worth approximately $25,000. Finally, Crewe Advisors LLC increased its stake in shares of Cooper Companies by 286.4% during the 2nd quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Price Performance

Shares of NASDAQ:COO opened at $110.49 on Friday. The firm has a market capitalization of $22.00 billion, a PE ratio of 64.99, a PEG ratio of 2.60 and a beta of 0.98. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The Cooper Companies, Inc. has a 1-year low of $75.93 and a 1-year high of $112.38. The business’s 50 day moving average is $97.54 and its 200-day moving average is $95.48.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, topping analysts’ consensus estimates of $0.91 by $0.05. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a net margin of 9.45% and a return on equity of 9.08%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.84 earnings per share. Sell-side analysts predict that The Cooper Companies, Inc. will post 3.66 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on COO shares. Stifel Nicolaus reiterated a “buy” rating and issued a $115.00 price objective (up from $110.00) on shares of Cooper Companies in a report on Thursday, August 29th. Morgan Stanley upped their price target on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Needham & Company LLC reissued a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and upped their target price for the stock from $107.00 to $115.00 in a research report on Tuesday, July 16th. Finally, Robert W. Baird lifted their price target on shares of Cooper Companies from $118.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, August 29th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $115.00.

Insider Activity at Cooper Companies

In other Cooper Companies news, CEO Albert G. White III sold 114,992 shares of Cooper Companies stock in a transaction that occurred on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total transaction of $12,710,065.76. Following the sale, the chief executive officer now directly owns 165,273 shares of the company’s stock, valued at $18,267,624.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $110.53, for a total value of $12,710,065.76. Following the sale, the chief executive officer now owns 165,273 shares of the company’s stock, valued at approximately $18,267,624.69. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Brian G. Andrews sold 24,788 shares of the stock in a transaction on Thursday, September 5th. The stock was sold at an average price of $105.90, for a total value of $2,625,049.20. Following the transaction, the chief financial officer now owns 6,614 shares of the company’s stock, valued at $700,422.60. The disclosure for this sale can be found here. Insiders have sold a total of 256,373 shares of company stock valued at $27,637,427 over the last quarter. 2.00% of the stock is owned by company insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.